Immunovant Inc (IMVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
Immunovant Inc (IMVT) Earnings: Report Dates and Results
Immunovant (IMVT) is expected to report earnings on Feb 4, 2027. In the quarter ended Sep 30, 2026, Immunovant reported EPS of -$0.47, above the -$0.73 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IMVT has an expected report date of Feb 4, 2027.
IMVT Earnings Call
The latest IMVT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 28 quarters below that had an estimate, IMVT beat 9, missed 18 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 35.71% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.47 | -$0.73 | -$0.76 - -$0.70 | +35.62% | Beat | N/A | 3 | 0 up, 1 down | Nov 9, 2026 | N/A |
| Jun 30, 2026 | -$0.75 | -$0.66 | -$0.75 - -$0.48 | -13.64% | Miss | N/A | 2 | 1 up, 0 down | Aug 6, 2026 | $7.09M |
| Mar 31, 2026 | -$0.67 | -$0.63 | -$0.73 - -$0.53 | -6.35% | Miss | N/A | 5 | 2 up, 0 down | May 20, 2026 | N/A |
| Dec 31, 2025 | -$0.54 | -$0.69 | -$0.76 - -$0.57 | +21.74% | Beat | N/A | 9 | 1 up, 0 down | Feb 6, 2026 | N/A |
| Sep 30, 2025 | -$0.65 | -$0.73 | -$0.80 - -$0.59 | +10.96% | Beat | N/A | 13 | N/A | Nov 10, 2025 | N/A |
| Jun 30, 2025 | -$0.71 | -$0.67 | -$0.77 - -$0.57 | -5.97% | Miss | N/A | 10 | 3 up, 0 down | Aug 11, 2025 | N/A |
| Mar 31, 2025 | -$0.64 | -$0.71 | -$0.86 - -$0.56 | +10.11% | Beat | N/A | 10 | 0 up, 0 down | May 29, 2025 | $160000 |
| Dec 31, 2024 | -$0.76 | -$0.75 | -$0.83 - -$0.56 | -1.33% | Miss | N/A | 9 | 1 up, 0 down | Feb 6, 2025 | N/A |
| Sep 30, 2024 | -$0.74 | -$0.59 | -$0.67 - -$0.46 | -25.42% | Miss | N/A | 14 | 1 up, 0 down | Nov 6, 2024 | N/A |
| Jun 30, 2024 | -$0.60 | -$0.52 | -$0.58 - -$0.46 | -15.38% | Miss | N/A | 10 | 0 up, 0 down | Aug 6, 2024 | N/A |
| Mar 31, 2024 | -$0.52 | -$0.43 | -$0.49 - -$0.35 | -20.93% | Miss | N/A | 14 | 0 up, 0 down | May 29, 2024 | $1.50M |
| Dec 31, 2023 | -$0.36 | -$0.42 | -$0.53 - -$0.30 | +14.29% | Beat | N/A | 13 | 0 up, 0 down | Feb 12, 2024 | N/A |
| Sep 30, 2023 | -$0.45 | -$0.46 | -$0.55 - -$0.34 | +2.17% | Beat | N/A | 12 | 2 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.57 | -$0.44 | -$0.51 - -$0.33 | -29.55% | Miss | N/A | 12 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.46 | -$0.41 | -$0.68 - -$0.19 | -12.20% | Miss | N/A | 13 | 0 up, 0 down | May 22, 2023 | N/A |
| Dec 31, 2022 | -$0.49 | -$0.37 | -$0.47 - -$0.31 | -32.43% | Miss | N/A | 7 | 0 up, 0 down | Feb 3, 2023 | N/A |
| Sep 30, 2022 | -$0.41 | -$0.36 | -$0.44 - -$0.33 | -13.89% | Miss | N/A | 8 | 0 up, 0 down | Nov 4, 2022 | N/A |
| Jun 30, 2022 | -$0.35 | -$0.40 | -$0.45 - -$0.32 | +12.50% | Beat | N/A | 7 | 0 up, 0 down | Aug 5, 2022 | N/A |
| Mar 31, 2022 | -$0.41 | -$0.38 | -$0.44 - -$0.30 | -7.89% | Miss | N/A | 7 | 1 up, 0 down | Jun 8, 2022 | N/A |
| Dec 31, 2021 | -$0.36 | -$0.31 | -$0.38 - -$0.29 | -16.13% | Miss | N/A | 8 | N/A | Feb 4, 2022 | N/A |
| Sep 30, 2021 | -$0.35 | -$0.27 | -$0.35 - -$0.22 | -29.63% | Miss | N/A | 7 | N/A | Nov 5, 2021 | N/A |
| Jun 30, 2021 | -$0.31 | -$0.31 | -$0.37 - -$0.28 | 0.00% | In line | N/A | 6 | N/A | Aug 9, 2021 | N/A |
| Mar 31, 2021 | -$0.29 | -$0.34 | -$0.44 - -$0.30 | +14.71% | Beat | N/A | 7 | N/A | Jun 1, 2021 | N/A |
| Dec 31, 2020 | -$0.32 | -$0.25 | -$0.29 - -$0.22 | -28.00% | Miss | N/A | 9 | N/A | Feb 16, 2021 | N/A |
| Sep 30, 2020 | -$0.25 | -$0.30 | -$0.38 - -$0.30 | +16.67% | Beat | N/A | 8 | N/A | Nov 12, 2020 | N/A |
| Jun 30, 2020 | -$0.38 | -$0.33 | -$0.38 - -$0.24 | -15.15% | Miss | -3900.0% | 5 | N/A | Aug 12, 2020 | N/A |
| Mar 31, 2020 | -$0.38 | -$0.28 | -$0.93 - -$0.19 | -35.71% | Miss | N/A | 6 | N/A | Jun 29, 2020 | $925798 |
| Dec 31, 2019 | -$0.28 | -$0.25 | N/A | -12.00% | Miss | N/A | N/A | N/A | Feb 14, 2020 | N/A |
| Sep 30, 2019 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 6, 2019 | N/A |
| Jun 30, 2019 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2019 | N/A |
| Mar 31, 2019 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Jun 12, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was -$2.57, after -$2.74 the year before. It was -$0.90 for the year ended Mar 31, 2020, the oldest of the 7 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | -$2.57 | N/A |
| Mar 31, 2025 | -$2.74 | N/A |
| Mar 31, 2024 | -$1.90 | N/A |
| Mar 31, 2023 | -$1.71 | N/A |
| Mar 31, 2022 | -$1.43 | N/A |
| Mar 31, 2021 | -$1.24 | N/A |
| Mar 31, 2020 | -$0.90 | N/A |
| Mar 31, 2019 | Not reported | N/A |
Earnings Calls
The 3 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,600 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,645 | 18 | |
| 2026Q2 | Jun 30, 2026 | 4,884 | 14 | |
| 2025Q2 | Jun 30, 2025 | 3,013 | 13 |
2026Q3 Earnings Call
Opening remarks
Stephanie Lee Griffin Investor Relations, Roivant Good morning, and thanks for joining today's call to review positive Phase II results for brepocitinib in cutaneous sarcoidosis and Roivant's financial results for the third quarter ended December 31, 2025. I'm Stephanie Lee with Roivant. Presenting today we have Matt Gline, CEO of Roivant; and Ben Zimmer, CEO of Priovant Therapeutics. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I would like to remind you that we will be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I'll turn it over to Matt.
Matthew Gline CEO, Roivant Thanks, Steph, and thanks, everyone, for dialing in and listening this morning. I'm going to start our presentation on Slide 5. I was sitting and talking to the team about a week ago today, looking at a draft of this morning's presentation and thinking that it was going to be a pretty boring 10-Q. We had gotten together in December for the Investor Day. We had spoken at the JPMorgan conference, and it turned out to have been a really busy week. So we have some great updates, obviously, most notably the Phase II data in brepocitinib in cutaneous sarcoidosis, which Ben is going to present on momentarily. But the truth is terrific execution and progress across the board for us this quarter. Obviously, that data is a highlight, but we also can announce today that the NDA for brepocitinib in dermatomyositis is in, that the Phase IIb study for IMVT-1402 in difficult-to-treat RA has fully enrolled, that the Phase II study for mosliciguat in PH-ILD has fully enrolled. And obviously, all of the updates that we're known for, including the Immunovant offering earlier that gets us now financed to greatest launch, are all behind us. So just a terrific quarter and a terrific set of updates even since early January when we last got together. On Slide 6, 2026 is, again, a very busy year for us ahead. Obviously, some major events later in the year: the brepocitinib NIU Phase III pivotal readout in the second half. We're now going to be starting this year a Phase III study in brepocitinib in cutaneous sarcoidosis. Ben will talk a little bit more about that. It's early days and we're getting that going, but that will be this year.
Frequently Asked Questions About IMVT
When is Immunovant's next earnings date?
Immunovant's next earnings report is expected for Feb 4, 2027.
Did IMVT beat earnings estimates last quarter?
Yes. Immunovant reported EPS of -$0.47 for the quarter ended Sep 30, 2026, above the -$0.73 estimate, a 35.62% surprise.
What EPS do analysts expect from IMVT next quarter?
The consensus EPS estimate for Immunovant for the quarter ending Dec 31, 2026 is -$0.58 from 3 analysts, with estimates from -$0.71 to -$0.50.
How often does IMVT beat earnings estimates?
Immunovant beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +6.39%.
IMVT pages: Overview, Earnings, Forecast, Financials, Competitors